Overview

Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study of ABT-869 in Combination with Tarceva in Subjects with Solid Tumors
Phase:
Phase 1
Details
Lead Sponsor:
Abbott
Collaborator:
Genentech, Inc.
Treatments:
Erlotinib Hydrochloride